Want to see TARS full AI Analyst Report?
Tarsus Pharmaceuticals (TARS) Stock Statistics & Valuation Metrics
Total Valuation
Tarsus Pharmaceuticals has a market cap or net worth of $3.69B. The enterprise value is $2.37B.
- Market Cap
- $3.69B
- Enterprise Value
- $2.37B
Share Statistics
Tarsus Pharmaceuticals has 49,303,413 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 49,303,413
- Owned by Insiders
- 2.75%
- Owned by Institutions
- 37.55%
Financial Efficiency
Tarsus Pharmaceuticals’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -16.64%.
- Return on Equity (ROE)
- -0.19
- Return on Assets (ROA)
- -0.12
- Return on Invested Capital (ROIC)
- -16.64%
- Return on Capital Employed (ROCE)
- -0.17
- Revenue Per Employee
- 1.22M
- Profits Per Employee
- -179.51K
- Employee Count
- 370
- Asset Turnover
- 0.80
- Inventory Turnover
- 7.02
Valuation Ratios
The current PE Ratio of Tarsus Pharmaceuticals is -67.27. Tarsus Pharmaceuticals’s PEG ratio is -0.80.
- PE Ratio
- -67.27
- PS Ratio
- 5.66
- PB Ratio
- 9.18
- Price to FCF
- 55.74
- Price to Operating Cash Flow
- 39.92
- PEG Ratio
- -0.80
Income Statement
In the last 12 months, Tarsus Pharmaceuticals had revenue of 451.36M and earned -66.42M in profits. Earnings per share was -1.59.
- Revenue
- 451.36M
- Gross Profit
- 420.68M
- Operating Income
- -70.97M
- Pretax Income
- -64.36M
- Net Income
- -66.42M
- EBITDA
- -53.61M
- Earnings Per Share (EPS)
- -1.59
Cash Flow
In the last 12 months, operating cash flow was 79.70M and capital expenditures -18.16M, giving a free cash flow of 61.55M billion.
- Operating Cash Flow
- 79.70M
- Free Cash Flow
- 61.55M
- Free Cash Flow per Share
- 1.42
Dividends & Yields
Tarsus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.79%
- Earnings Yield
- -1.46%
Stock Price Statistics
- Beta
- 0.25
- 52-Week Price Change
- 6.55%
- 50-Day Moving Average
- 75.52
- 200-Day Moving Average
- 67.78
- Relative Strength Index (RSI)
- 55.11
- Average Volume (3m)
- 814.37K
Important Dates
Tarsus Pharmaceuticals upcoming earnings date is Nov 03, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Nov 03, 2026
- Ex-Dividend Date
- ―
Financial Position
Tarsus Pharmaceuticals as a current ratio of 3.85, with Debt / Equity ratio of 27.27%
- Current Ratio
- 3.85
- Quick Ratio
- 3.82
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- 1.68
- Interest Coverage Ratio
- -7.94
Taxes
In the past 12 months, Tarsus Pharmaceuticals has paid 2.06M in taxes.
- Income Tax
- 2.06M
- Effective Tax Rate
- -0.03
Enterprise Valuation
Tarsus Pharmaceuticals EV to EBITDA ratio is -93.97, with an EV/FCF ratio of 53.86.
- EV to Sales
- 5.47
- EV to EBITDA
- -93.97
- EV to Free Cash Flow
- 53.86
- EV to Operating Cash Flow
- 41.59
Balance Sheet
Tarsus Pharmaceuticals has $449.69M in cash and marketable securities with $88.66M in debt, giving a net cash position of $361.03M billion.
- Cash & Marketable Securities
- $449.69M
- Total Debt
- $88.66M
- Net Cash
- $361.03M
- Net Cash Per Share
- $7.32
- Tangible Book Value Per Share
- $7.83
Margins
Gross margin is 90.59%, with operating margin of -8.00%, and net profit margin of -7.67%.
- Gross Margin
- 90.59%
- Operating Margin
- -8.00%
- Pretax Margin
- -7.27%
- Net Profit Margin
- -7.67%
- EBITDA Margin
- -5.82%
- EBIT Margin
- -6.19%
Analyst Forecast
The average price target for Tarsus Pharmaceuticals is $100.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $100.13
- Price Target Upside
- 36.56% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- 105.17%
- EPS Growth Forecast
- 53.58%
Scores
- Smart Score
- 9
- AI Score
- 65
